Latest News Archive
Please select Category, Year, and then Month to display items
04 April 2024
|
Story Lunga Luthuli
|
Photo SUPPLIED
Dr Juliet Kamwendo champions gender-inclusive climate action in Africa. Her expertise at the recently held AFR100 workshop highlighted vital steps towards sustainable and equitable development.
Dr Juliet Kamwendo, Lecturer and Programme Director for Gender Studies in the Centre for Gender and Africa Studies at the University of the Free State, is spearheading efforts to integrate gender considerations into Africa's climate restoration agenda. Reflecting on her involvement, Dr Kamwendo stated, "This is particularly crucial, as women make up almost 50% of the population in Africa, and the depletion and degradation of land affect them disproportionately."
She recently served as a gender expert at the AUDA-NEPAD AFR100 workshop in Ouagadougou, Burkina Faso, from 25 to 29 March 2024. This initiative aims to restore forests and degraded land across Africa by 2030, with a focus on gender equality.
The workshop emphasised the integration of gender perspectives into the AFR100 project, acknowledging the disproportionate impact of land degradation on women. Dr Kamwendo's expertise highlighted the need to empower women in climate change interventions, addressing existing gender inequalities exacerbated by environmental degradation.
“Women – who are primarily responsible for household food security and water provision – bear the brunt of environmental degradation, leading to increased workloads, reduced income opportunities, and heightened vulnerability to climate-related disasters. Furthermore, the loss of forest cover and biodiversity further exacerbates the challenges faced by women, particularly in rural areas where they depend heavily on natural resources for their livelihoods,” added Dr Kamwendo.
Her participation highlights academia's crucial role in fostering inclusive and sustainable development, emphasising interdisciplinary collaboration to tackle complex environmental challenges. Through initiatives such as AFR100, stakeholders are working towards a more resilient and gender-responsive future for Africa.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004